CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)

Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm

newsfileApr 24 15:17 ET

CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)

Toronto, Ontario--(Newsfile Corp. - le 5 mars/March 2024) - Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading. The Company has rectified the situation that gave rise to the

newsfileMar 5 13:54 ET

Canadian Investment Regulatory Organization Trading Halt - TRYP

Stockhouse Feb 5 08:10 ET

Tryp Therapeutics and Exopharm Limited Secures Pivotal $0.02 Waiver From ASX

Tryp Therapeutics, Inc. (TRYP.CN), a biotechnology company developing intravenous-infused psilocin, on Friday announced that Tryp and Exopharm Limited have been granted a pivotal $0.02 waiver by the Australian Securities Exchange.

MT NewswiresJan 26 07:09 ET

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803...

Stockhouse Jan 8 07:00 ET

Tryp Therapeutics Says First Patient Dosed in Phase 2a Clinical Trial for Treatment of Fibromyalgia at University of Michigan

Tryp Therapeutics, Inc. (TRYP.CSE), a biotechnology company developing intravenous-infused psilocin, on Thursday said the first patient has been dosed in a Phase 2a clinical trial evaluating Tryp's TR

MT NewswiresJan 4 07:18 ET